The Global Asthma Inhaler Devices Market is growing exponentially owing to rising prevalence of chronic respiratory disease and increasing usage of combination therapy are the major factor driving the Asthma Inhaler Devices Market. The Global Asthma Inhaler Devices Market is expected to grow at a CAGR of 6% during the forecasted period.
Asthma, an inflammatory disease of the lungs is characterized by difficulty while breathing. The symptoms can be triggered by exposure to various types of allergens such as pollen, ragweed, animal dander, and irritants such as smoke and chemical fumes. Common symptoms of asthma are coughing, wheezing, tightness in the chest, and shortness of breath. It leads to swelling or inflammation of inside walls of an asthmatic’s airways. This makes the airways extremely sensitive to irritations and increases the susceptibility to an allergic reaction. Asthma is found to be common among children that result in loss of their productivity.
The Global Market for Asthma Inhaler Devices is growing and is mainly driven by the rise in the prevalence of asthma, especially among children. Additionally, there is an increase in the demand for metered dose inhalers and increasing awareness about lung diseases. The increasing expenditure by medical devices companies also has a synergistic effect on the market.
Global Asthma Inhaler Device Market – Key Players
Some of the key players in this market are GlaxoSmithKline Plc. (U.K), Merck & Co., Inc. (US), 3M (US), Aristopharma Ltd. (Bangladesh), SRS PHARMACEUTICALS PVT. LTD. (India), Intas Pharmaceuticals, Ltd. (India), and others.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1653
Global Asthma Inhaler Device Market – Industry Updates
Feb, 2017 BI received expantion of FDA approval of the use of Tiotropium Respimat for treatment of Asthma in Children. With this approval, company will be able to sell the product inside the United States.
Jan, 2017 AstraZeneca announced that on 25 January 2017 the US Food and Drug Administration (FDA) granted six months of paediatric exclusivity for Symbicort (budesonide/formoterol) Inhalation Aerosol. Symbicort is approved in the US to treat asthma in patients 12 years and older and for the maintenance and treatment of COPD in adults, the company is expecting larger market share with the product launch.
Nov, 2016 Chiesi acquires Atopix therapeutics. The acquisition of the UK based clinical stage biotechnology company will help Chiesi enhance its Asthma Segment.
Feb, 2015 AstraZeneca and Actavis Plc have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above certain revenue threshold.
Global Asthma Inhaler Device Market – Segmentation
The Global Asthma Inhaler Device Market is divided into device type, technology, and end-user.
On the basis of device type, the market is segmented into metered-dose inhaler, MDI with a spacer, dry-powder inhaler, and others.
On the basis of technology, the market is segmented into manually operated inhaler devices and digitally operated inhaler devices.
On the basis of end-user, the market is segmented into hospital, clinics, research institutes, and others.
Global Asthma Inhaler Device Market – Regional Analysis
Depending on geographic region, Globally North America is the largest market for Asthma Inhalers. Currently there are around 6.4% of American suffering from COPD in U.S. and around 5.4 million people suffering from asthma in U.K. This major growth is attributed to the popularity of the dry powder inhalers among population due to its several advantages over Metered Dose Inhalers and other types of inhalers.
To Know More Enquire @ https://www.marketresearchfuture.com/enquiry/1653
Europe is the second-largest market for asthma inhalers. It is observed that almost 70% of the child’s death occurred per year due to respiratory disorders are due to these sudden attacks hence rescue medication or rescue inhalers can serve better to save lots of lives per year.
Asia pacific region is expected to be fastest growing region in respiratory Inhaler market. Middle East & Africa is expected to have limited but steady growth in the market. These countries with the advancement of technology are expected to show large number of cases of asthma and other respiratory disease which remain unnoticed currently.
Major Table of Content
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope of the Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar